This content was written and submitted by the supplier. It has only been modified to comply with this publication’s space and style.
Cryoport's Chief Commercial Officer, Mark W. Sawicki, Ph.D., announced changes to the US sales organization, which includes a restructuring of territories and the addition of five new Sales Directors with more than 120 years of aggregated experience in the fields of cold chain logistics, healthcare, clinical trial management and life sciences. These new Sales Directors will play a critical role in building upon and accelerating Cryoport's record of growth and innovation as the leading provider of cryogenic logistics solutions to the life sciences. This expansion will significantly enhance the existing sales efforts and better enable Cryoport to meet the rapidly growing demand for frozen logistics solutions by the life sciences industry at large.
Mark Sawicki states, "The life sciences industry is entering a new, era of innovation, including advances in biopharmaceuticals, immunotherapies, vaccinations and regenerative medicine. As the premier cryogenic logistics provider and the preferred partner of the world's largest shipping companies, Cryoport is continuously innovating and evolving to meet the needs of a life sciences industry where secure, track-able cryogenic transfer of biomaterials is either mandated or mission critical. With this expansion of our sales team, Cryoport is better positioned than ever before to capitalize on the fastest growing segments of the market, such as stem cells and CAR-T Cell therapies.
Jerrell Shelton, CEO of Cryoport, commented, "The life sciences industry continues to evolve and exhibit explosive growth globally. The fact that most new cell based products must be shipped in controlled cryogenic conditions and many of the new critical experimental vaccines for Ebola and Malaria require cryogenic solutions to support vaccine efficacy and distribution into regions with limited infrastructure creates an abundance of opportunities for Cryoport. With regulatory requirements becoming increasingly stringent and cryogenic shipping now mandated for many new therapeutic areas, the addition of these highly skilled and experienced personnel to our sales force will enable us to capitalize on what we see as an unprecedented market opportunity where Cryoport is already recognized as the clear leader with unique competencies."
